Skip to main content

Site notifications

MALTOFER Tablets, Vifor Pharma Pty Ltd, CON-1119

Product name
MALTOFER Tablets
Sponsor name
Vifor Pharma Pty Ltd
Consent start
Consent no.
CON-1119
Duration
The consent is effective from 20 June 2023 until 20 June 2025.
Standard
paragraphs 10 (8)(a)(v), 10 (8)(a)(vi) and 10 (8)(a)(vii) of Therapeutic Goods Order No. 92 - Standard for labels of non-prescription medicines
Non-compliance with standard
• The name on the proposed blister label is ‘Maltofer’, instead of Therapeutic Goods Administration (TGA) approved product name ‘Maltofer Tablets’. • The name of the active ingredient on the proposed blister label is ‘iron as iron (III)-hydroxide polymaltose complex (IPC)’, instead of ‘iron as iron polymaltose’ on the TGA approved blister label. • The quantity of iron on the proposed blister label is depicted as 100 mg, instead of 100 mg iron as 370 mg iron polymaltose presented on the TGA approved blister label.
Import, Supply, &/or Export
import and supply
Therapeutic product type
Over-the-counter medicines